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Abstract
Introduction: Papillary thyroid carcinoma (PTC) is the most common malignant thyroid tumour. A great majority of the cases live 
a disease-free life with quite favourable prognosis. There are lots of variants of PTC, and a few of them exhibit aggressive behaviour. 
A typical example is the tall cell variant (TCV). Patients experience a greater incidence of recurrence, nodal and extranodal metastases, and 
tumour-associated mortality than in other variants of PTC. Studies related to TCV almost always compared it with its patient population of 
PTC according to risk factors and clinicopathological features. The aim of this study is to evaluate the risk factors in metastatic/recurrent TCV. 
Materials and methods: This is a retrospective cohort study of 1813 patients with differentiated thyroid carcinoma treated with radi-
oiodine between 1992 and 2011. Fifty-six of these patients are TCV. Thirty-four of them developed metastasis/recurrence, and 22 lived 
a disease-free life during a follow-up time of 4–23 years. We evaluated the risk factors in these metastatic and non-metastatic subgroups. 
Results: We found tumour size, pre-ablation thyroglobulin level, vascular invasion, pre-ablation central and lateral cervical lymph node 
metastasis, pre-ablation lung metastasis, and stage-independent risk factors. However, age, pre-ablation thyroglobulin level, and stage 
appeared together as striking factors impacting metastasis in multivariate analysis. 
Conclusion: Higher ablation doses up to 250–300 mCi should be administered to TCV patients having advanced stage (III, IV), moderately 
high pre-ablation thyroglobulin level (over 400 ng/ml), and older age (over 52 years) especially with large tumour size (over 3.5 cm) and 
initial cervical lymph node metastasis. (Endokrynol Pol 2017; 68 (6): 623–630)
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Streszczenie
Wstęp. Rak brodawkowaty tarczycy (papillary thyroid carcinoma, PTC) jest najczęstszym nowotworem złośliwym tego narządu. 
U przeważającej większości chorych możliwe jest całkowite wyleczenie, a rokowanie jest dobre. Występuje wiele odmian PTC, spośród 
których nieliczne są bardziej agresywne. Typowym przykładem takich nowotworów jest odmiana wysokokomórkowa (tall cell variant, 
TCV). Cechuje się ona częstszym występowaniem wznów, przerzutów do węzłów chłonnych i pozawęzłowych oraz większą śmiertelnością 
z powodu choroby nowotworowej niż inne odmiany PTC. Badania dotyczące TCV niemal zawsze mają na celu porównanie tej grupy 
chorych z populacją chorych na PTC w odniesieniu do czynników ryzyka oraz parametrów klinicznych i patomorfologicznych. Celem 
niniejszego badania jest ocena czynników ryzyka w przerzutowym/nawrotowym TCV. 
Materiał i metody. Było to retrospektywne badanie kohortowe obejmujące 1813 chorych ze zróżnicowanym rakiem tarczycy leczonych 
jodem promieniotwórczym w latach 1992–2011. U 56 osób z tej grupy rozpoznano TCV. U 34 z nich stwierdzono przerzut/nawrót, 
a w przypadku 22 chorych potwierdzono przeżycie wolne od choroby przez okres 4–23 lat. Autorzy ocenili czynniki ryzyka w podgrupach 
chorych z przerzutami i bez przerzutów. 
Wyniki. Stwierdzono, że niezależnymi czynnikami ryzyka są wielkość guza, stężenie tyreoglobuliny przed ablacją, unaczynienie guza, 
przerzuty to węzłów chłonnych szyjnych środkowych i tylnych oraz do płuc przed ablacją, a także stopień zaawansowania choroby. 
Jednak najważniejszymi czynnikami ryzyka przerzutów w analizie wieloczynnikowej okazały się wiek, stężenie tyreoglobuliny przed 
ablacją i stopień zaawansowania choroby nowotworowej.
Wnioski. U chorych z TCV w zaawansowanym stadium (III, IV), z wysokimi stężeniami tyreoglobuliny (> 400 ng/ml) i w starszym wieku 
(> 52 lata), a zwłaszcza u osób z dużym rozmiarem guza (> 3,5 cm) i obecnymi przerzutami do węzłów chłonnych szyjnych, należy 
stosować wyższe dawki ablacyjne wynoszące do 250–300 mCi. (Endokrynol Pol 2017; 68 (6): 623–630)
Słowa kluczowe: odmiana wysokokomórkowa, rak brodawkowaty tarczycy, prognostyczne czynniki ryzyka
Introduction
Papillary thyroid carcinoma (PTC) is the most fre-
quent endocrine malignancy and the most common 
malignant thyroid tumour. A great majority of cases 
live a disease-free life with good prognosis. There are 
many variants of PTC, and only a few of them exhibit 
aggressive behaviour. A typical example is the tall cell 
variant (TCV). TCV frequently presents itself with 
extra-thyroidal disease. Patients with TCV experience 
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greater incidence of recurrence, nodal and extranodal 
metastases, and tumour-associated mortality than the 
other variants of PTC [1, 2]. These metastases are usu-
ally seen in cervical lymph nodes. Distant metastatic 
sites for TCV are lungs, bones, and rarely brain and 
liver.
TCV is composed of tall papillary epithelial cells hav-
ing a height at least two-times greater than the width, 
and elongated hyperchromatic nuclei oriented towards 
the basement membrane in a substantially eosinophilic 
cytoplasm containing a portion minimally larger than 
30% of the cells within the tumour [2, 3]. The incidence 
of TCV has been reported to be between 3.8% and 10.4% 
in published series [1, 4, 5]. The major controversy in 
terms of the diagnostic classification of a thyroid cancer 
as TCV is the quantity of tall cell pattern in the tumour 
[6, 7]. According to the WHO, tall cells should compose 
at least 30–50% of the tumour for classifying a tumour 
as TCV [8, 9]. 
Although there are some studies indicating that poor 
prognosis in this disease is associated with stage, grade, 
and age over 50 years, rather than histology, TCV is 
generally accepted as an independent poor prognostic 
factor in the literature [1, 3, 6, 7]. These tumours occur in 
older ages (average age of occurrence is 55 years), show 
gross extra-thyroidal extension and vascular invasion, 
and they are generally larger tumours (4 cm on aver-
age) than well-differentiated PTC [9, 10]. Its malignant 
behaviour was attributed to these properties initially. 
But later on, it was noticed that metastasis could also 
be seen in intra-glandular TCV without extra-thyroidal 
extension, in tumours even smaller than 1.5 cm or in 
younger cases. Currently there are no studies with 
enough samples and long-term follow-up data show-
ing the real impact of these or other risk factors on 
metastatic potential.
The reason for the aggressiveness associated with 
molecular base, genetic, and tumoural factors is not 
known. Overexpression of Mucl1 and type IV col-
lagenase in these tumours may be responsible for 
the invasive character by degrading stroma [11–13]. 
A higher prevalence of activating point mutation B-RAF 
rather than PTC may also be a reason [14, 15]. It was 
shown that any subtype of PTC with B-RAF mutation 
has more extra-thyroidal extension, LN metastasis, and 
higher stage than B-RAF negative ones [8, 16]. TCV is 
generally sensitive to radioactive iodine (I-131, RAI) 
[10, 17]. 20% of FDG/PET-positive, radioiodine-negative 
tumours are TCV, and 88% of I-131 refractory tall cell 
variants have extra-thyroidal extension [11, 18]. The aim 
of the study is to evaluate the risk factors in metastatic/ 
/recurrent TCV of PTC. This is the first study in literature 
comparing metastatic and non-metastatic TCV based 
on predefined risk factors.
Material and methods
This is a retrospective cohort study. 1813 patients with 
differentiated thyroid carcinoma (DTC) were treated with 
I-131 between 1992 and 2011. They were followed-up 
until 2015 (during a period of 4–23 years) by the Nuclear 
Medicine Department of Gulhane Training and Research 
Hospital, Ankara, Turkey. Fifty-nine patients were con-
firmed pathologically as TCV between 1992 and 2011. 
TCV diagnosis was established pathologically according 
to WHO classification criteria on the basis of tall cell pat-
tern dominating more than 30% of the tumoural area. 
Tall cell pattern is characterised by being at least twice as 
tall as its width, having an eosinophilic cytoplasm and 
a hyperchromatic basilar nucleus. Histology slides were 
re-examined by another experienced pathologist for con-
firmation. Three cases of 59 patients were excluded from 
the study because of inadequate follow-up. Patients diag-
nosed as TCV after 2011 were not enrolled in the study.
All patients underwent bilateral total thyroidectomy 
(plus radical neck dissection if there was cervical LN 
metastasis) after the histopathological diagnosis. RAI ab-
lation treatment was planned according to tumour size 
(TS), multifocality (MF), thyroid capsule invasion (CI), 
extra-thyroidal extension (ETE), vascular invasion (VI), 
and existence of LN and/or distant metastasis, and it was 
scheduled 4–6 weeks after the surgery or cessation of 
thyroxin replacement therapy (TSH levels should be at 
least over 30 mIU/L). Neck ultrasonography (USG) was 
used to identify possible cervical LN metastasis and/or 
residual thyroid tissue in the thyroid bed; and serum 
thyroid stimulating hormone (TSH), thyroglobulin 
(Tg), anti-Tg were measured 1 to 24 hours before the 
ablating RAI treatment. A post-treatment I-131 whole-
body screening scintigraphy (RxWBS) was performed 
for all the cases five days after the RAI treatment. If any 
uptake in regions consistent with lungs or bones was ob-
served, they were considered distant organ metastases 
and were taken into account for staging. After primary 
treatment, all patients received thyroxine hormone re-
placement therapy in suppressive doses. Patients were 
followed by serum Tg, anti-Tg, TSH levels, and neck 
USG every six months in the first two years and then on 
a yearly basis, to detect local and/or distant metastasis. 
Whole-body screening test with 185 MBq (5 mCi) I-131 
(DxWBS) was performed six months (for assessing abla-
tion response), one year, two years, and five years after 
the treatment. Other imaging techniques such as X-ray, 
computed tomography (CT), high-resolution computed 
tomography (HRCT), magnetic resonance imaging 
(MRI), bone scintigraphy, positron emission tomogra-
phy (FDG-PET from 2006 to 2010), and FDG-PET/CT 
(from 2010) were performed when needed. LNs causing 
a suspicion of metastasis as a result of USG follow-up were 
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examined histologically with fine-needle aspiration bi-
opsy and excised after confirmation or excised directly for 
histopathological confirmation followed by high-dose 
RAI treatment. A significant increase in Tg levels (over 
10 ng/ml) in the follow-up without a demonstrable 
metastatic foci detected by routine imaging methods was 
considered as a possible metastasis, and therefore other 
imaging tests were performed for further investigation. 
The cases were staged according to the seventh edition 
of AJCC. The cases followed-up inadequately or for less 
than four years were excluded from the study.
The files of TCV patients were examined retrospec-
tively. Patients were divided into two groups according 
to follow-up data. Cases having distant metastases (lung 
and/or bone, brain, liver), LN metastases (regional and/ 
/or distant), and/or local recurrence during the follow-up 
(after initial thyroid surgery and ablative I-131 therapy) 
formed the metastatic/recurrent group (MG). Those not 
having metastasis/recurrence formed the non-metastatic 
group (NMG). The evaluated risk factors are age, sex, 
TS, MF, CI, ETE, VI, LN, existence of a distant metastasis 
before the ablation treatment (PACLNM: pre-ablation 
central lymph node metastasis, PACLLNM: pre-ablation 
cervical lateral lymph node metastasis, PALM: pre-
ablation lung metastasis, PABM: pre-ablation bone me-
tastasis), PAsTg: pre-ablation Tg level (1 to 24 hours before 
the ablation treatment), and the stage. These risk factors 
were compared in MG and NMG. The existence of ETE 
was accepted as tumoural infiltration beyond the thyroid 
capsule (perithyroidal adipose tissue, muscles, tracheal 
invasion, carotid vessel invasion). Overall survival (OS) 
was defined as the time from diagnosis to death due to 
the disease itself or until the last follow-up. Disease-free 
survival (DFS) was defined as the time from diagnosis 
to the detection of relapse or until the last follow-up.
The whole data were analysed by Statistical Pack-
age for Social Science (SPSS 15.0, Chicago, IL) software. 
Number, percentage, mean, median, standard deviation 
(SD), and minimum (min) and maximum (max) values 
were used for the description of data analysis. Accord-
ance of continuous variables to normal distribution was 
measured with Kolmogorov-Smirnov test. Student’s t 
(age) or Mann Whitney-U (TS, PAsTg) test was used for 
continuous variables; and Chi square (PALM, PABM) or 
Fisher’s exact (sex, MF, CI, ETE, VI, PACLNM, PACLLNM 
and stage) test for categorical variables in the comparisons 
between groups. Backward LR (logistical regression) 
analysis was performed for clarification of risk factors that 
affect the development of metastasis. Values of p < 0.05 
were accepted as statistically significant. Informed consent 
was deemed as a retrospective study using records, docu-
ments, and data of patients referred to our clinic for I-131 
therapy and later follow-up. This study was approved by 
our Institutional Review Board Ethics Committee.
Results
Fifty-six patients with TCV were followed-up for 
a duration of 4–23 years, and TCV incidence was 3.2% 
in our DTC patient population. Mean follow-up dura-
tion of patients was 97.5 ± 42 months (8–190 months). 
Mean follow-up duration was 105 ± 37 months (47–178 
months) in the NMG and 92.5 ± 44 months (8-190 
months) in the MG. Mean I-131 dose administered 
to patients was 11396 ± 8954 MBq (2775–48100 MBq). 
Mean I-131 dose administered was 5920 ± 1776 MBq 
(2775–11100 MBq) in the NMG and 14948 ± 9990 MBq 
(3700–48100 MBq) in the MG. 
Mean age (at diagnosis), mean TS, and mean PAsTg 
of patients were 49 ± 15.5 years (19–80 years), 27.5 ± 
19.5 mm (4–85 mm), and 290.5 ± 90 ng/ml, respectively. 
The values of these continuous variables belonging to 
groups and their comparisons are summarised in Table 
I. Sixty-six per cent of the patients were female and 
34% were male (female/male ratio: 1.95). The tumour 
was multifocal in 46.5% of the patients. CI was positive 
in 64% of the patients. ETE was seen in 35.5% of the 
patients. 37.5% of the patients were VI (+). 37.5% of 
the patients had central LN metastasis before ablation 
therapy. 44.5% of the cases had lateral LN metastasis 
before ablation therapy. PALM rate was 7/56 (12.5%) 
and PABM was 5/56 (9%). 48% of the patients were at 
stage I, 11% at stage II, 11% at stage III, and 30% at stage 
IV. The bar graphic in Figure 1 presents the categori-
cal variables of MG and NMG. These categorical risk 
Figure 1. Bar graphic of metastatic/recurrent group (MG) 
and non-metastatic group (NMG) by CI, ETE, VI, PACLNM, 
PACLLNM, and MF
Rycina 1. Wykres słupkowy przedstawiający CI, ETE, VI, 
PACLNM, PACLLNM i MF w grupach z przerzutem/nawrotem 
(MG) i bez przerzutu/nawrotu (NMG)
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factors in MG and NMG, and comparisons between 
these two groups afre also illustrated in Table II. We 
found TS, PAsTg, VI, PACLNM, PACLLNM, PALM, and 
stage to be statistically significant; whereas age, sex, 
MF, CI, ETE, and PABM were considered statistically 
insignificant (Table I, II). Age, PAsTg, and stage III were 
determined as primary risk factors in metastatic group 
according to LR analysis (Table III).
Thirty-four cases (61%) developed metastasis/re-
currence, and 22 cases (39%) had a disease-free (total 
remission) life. While all the patients in MG had LN 
metastasis/local recurrence, lung metastasis (seven 
diffuse, five focal) was observed in 12 (21.5%) cases 
and bone metastasis in six (10.5%) cases during the 
follow-up. Bone metastases of a patient detected by 
bone scintigraphy are shown in Figure 2. LN (cervical 
Table I. Comparison of metastatic/recurrent and non-metastatic group by age, tumour size, PAsTg
Tabela I. Porównanie wieku, wielkości guza i PAsTg w grupach z przerzutem/wznową i bez przerzutu
Variables Metastatic/recurrent group Non-metastatic group p value
Mean ± SD Mean ± SD
Age (year) 51.4 ± 14.4 45.4 ± 17.3 0.165a
Tumour size [mm] 31.4 ± 19.1 21.2 ± 19.0 0.007*
PAsTg [ng/ml] 403.7 ± 269.7 160.2 ± 48.0 < 0.001*
 
aStudent t test*: Mann Whitney-U test; PAsTg — pre-ablation Tg levels immediately prior to the treatment
Table II. Comparison of metastatic/recurrent and non-metastatic group by other variables
Tabela II. Porównanie innych zmiennych w grupach z przerzutem/wznową i bez przerzutu
Variables Metastatic/recurrent group Non-metastatic group pa
n % n %
Sex Male 14
20
41.2
58.8
5
17
22.7
77.3
0.154
Female
Multifocality 1 focus 17
17
50.0
50.0
13
9
59.1
40.9
0.505
2 or over
Capsule invasion Exist 25
9
73.5
26.5
11
11
50.0
50.0
0.073
Not exist
Extra-thyroidal extension Exist 13
21
38.2
61.8
7
15
31.8
68.2
0.625
Not exist
Vascular invasion Exist 17
17
50.0
50.0
4
18
18.2
81.8
0.016
Not exist
PACLNM Exist 18
16
52.9
47.1
3
19
13.6
86.4
0.003
Not exist
PACLLNM Exist 21
13
61.8
38.2
4
18
18.2
81.8
< 0.001
Not exist
PALM Exist 7
27
20.6
79.4
0
22
0
100
0.035*
Not exist
PABM Exist 5
29
14.7
85.3
0
22
0
100
0.145*
Not exist
Stage I 10
6
5
13
29.4
17.6
14.7
38.2
17
0
1
4
77.3
0
4.5
18.2
0.004
II
III
IV
aChi-square test; *Fisher’s exact test; PACLNM — pre-ablation central lymph node metastasis; PACLLNM — pre-ablation cervical lateral lymph node metastasis; 
PALM — pre-ablation lung metastasis; PABM — pre-ablation bone metastasis
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and/or distant) metastasis was detected in 50% of the 
patients during the follow-up period. Mean occurrence 
time of metastasis after diagnosis (disease-free interval) 
was 24 months (6–60 months). Secondary malignancies 
developed in six patients during the follow-up. Breast 
cancer, prostate cancer, lung cancer, and nasopharynx 
cancer were diagnosed in four cases in MG. Basal cell 
adenocarcinoma of parotid gland and colon cancer were 
seen in two cases in NMG. We detected local recurrence/ 
/LN metastasis and/or distant metastasis (LN, lung, 
bone) by FDG-PET in seven cases out of nine patients 
whose DxWBSs were negative. Lung and LN metasta-
ses of a patient whose DxWBS was negative were seen 
on FDG-PET (Figure 3). In these cases Tg levels were 
Table III. Risk evaluation with logistical regression analysis in metastatic / recurrent tall cell variant of papillary thyroid cancer
Tabela III. Ocena ryzyka za pomocą analizy regresji logistycznej w odmianie wysokokomórkowej przerzutowego/nawrotowego 
raka brodawkowatego tarczycy
Variable (Referans) B OR (95% CI) p value
Age –0.170 0.844 (0.730–0.976) 0.022
PAsTg 0.133 1.143 (1.008–1.295) 0.037
Sex (female) –2.414 0.089 (0.004–2.074) 0.132
Stage (Stage I) II 26.743 —
III 6.151 469.1 (3.4–64000) 0.014
IV 3.949 51.9 (0.88–3062) 0.058
Figure 2. A 72-year-old female patient of TCV with TS: 8 cm, multifocal, CI (+), ETE (+), VI (+), PACLLNM (+), stage IV, PAsTg 
> 300 ng/ml was given 9250 MBq (250 mCi) I-131 for ablation. DxWBS at sixth month was negative, but the patient had lung (on 
HRCT) and bone metastasis (on bone scintigraphy) and sTg > 300 ng/ml. The patient died eight months after the diagnosis. A. RxWB 
screening test five days after 9250 MBq I-131 ablation therapy exhibited intense uptake in the thyroid bed; B. Bone scintigraphy showed 
uptakes on upper medial part of left scapula (long arrow) and medial portion of right tibia (long arrow) consistent with bone metastasis
Rycina 2. Pacjentka w wieku 72 lat z rozpoznaniem TCV. Wielkość guza: 8 cm, zmiany wieloogniskowe, CI (+), ETE (+), VI (+), 
PACLLNM (+), stopień IV, PAsTg > 300 ng/ml. Zastosowano ablację I-131w dawce 9250 MBq (250 mCi). Diagnostyczna scyntygrafia 
całego ciała (DxWBS) po 6 miesiącach była ujemna, jednak u pacjentki stwierdzono przerzuty do płuc (w tomografii komputerowej 
wysokiej rozdzielczości HRCT) i kości (w scyntygrafii kości) oraz sTg > 300 ng/ml. Pacjentka zmarła po 8 miesiącach od postawienia 
diagnozy. A. Badanie RxWBS wykonane 5 dni po ablacji I-131 w dawce 9250 MBq wykazało intensywny wychwyt w loży tarczycy; 
B. Scyntygrafia kości wykazała ogniska wychwytu w górnej środkowej części łopatki (długa strzałka) i środkowej części kości piszczelowej 
prawej (długa strzałka) odpowiadające przerzutom do kości
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substantially high, leading us to consider possible me-
tastasis. They were treated by higher I-131 doses after 
surgical excision. In two cases in which both FDG-PET 
and DxWBS were negative, a persistently high Tg (1386 
ng/ml) level was the only indicator of metastasis in one 
of the cases. In another case with negative DxWBS, 
bone scintigraphy detected vertebral metastasis, and 
therefore radiotherapy was required.
Nine patients in the MG died due to the disease 
and disease-related complications. Two out of these 
nine patients died of brain metastasis; while the rest 
of them died because of cardiopulmonary disorders 
caused by the disease and its complications. The only 
patient who died in the NMG was a female aged 80 
years, and probably she did not die of TCV. In the cases 
who died in the MG, mean age was 65 years, mean TS 
was 42 mm, and mean PAsTg was 684 ng/ml; 55.5% 
of the patients were male; 55.5% of the tumours were 
multifocal, 66.5% CI (+), 33.5% ETE (+), and 77.5% VI 
(+); 55.5% of the patients were PACLNM (+), 66.5% 
PACLLNM (+), 55.5% PALM (+), and 55.5% PABM 
(+); 77.5% of the patients were at stage IV; mean ad-
ministered dose was 17464 MBq; and the mean study 
period was 81 months. 
Discussion
In spite of some recent studies claiming that TCV histol-
ogy does not adversely affect the prognosis, TCV itself 
is still a negative prognostic indicator [19]. Although 
studies on the prognosis of TCV and other stubborn 
variants have been performed, knowledge about their 
biological behaviour remains unclear because of the 
lack of studies involving a large number of patients [20]. 
The studies in the literature related to TCV almost al-
ways compared it with its PTC patient population with 
regard to risk factors and clinicopathological features. 
Our study is the first one in the literature in which 
metastatic and non-metastatic subgroups of TCV were 
followed-up for a long time and were compared with 
each other regarding well-known risk factors. We also 
studied some additional risk factors that were not used 
in other studies when comparing these two groups. 
TCV incidence in our patient population (3.2%) was 
below the incidence in the literature in general. The 
mean age of patients with TCV in reported series are 
around 53 years [9, 10] whereas the mean age of our 
patients (49 years) was lower than the literature. We 
attribute this fact to the early diagnosis by improved 
Figure 3. A 61-year-old female patient of TCV with TS: 12 mm, CI (-), VI (+), PACLLNM (+), stage II, PAsTg: 0.2 ng/ml was given 
7400 MBq (200 mCi) I-131 for ablation. She had multiple distant lymph nodes and multiple nodular lung metastasis seven years later 
(on FDG-PET). A. DxWBS was negative and sTg: 0.9 ng/ml; B. Multiple metastatic lymph nodes in right supraclavicular region (SUV 
max: 28.6) and multiple metastatic nodular lung metastasis, as the largest in the anterior segment of the right upper lung (SUV max: 
6.6), were seen on FDG-PET MIP images
Rycina 3. Pacjentka w wieku 61 lat z rozpoznaniem TCV. Wielkość guza: 12 mm, CI (-), VI (+), PACLLNM (+), stopień II, 
PAsTg: 0,2 ng/ml. Zastosowano ablację I-131 w dawce 7400 MBq (200 mCi). Po 7 latach u chorej stwierdzono liczne przerzuty 
w odległych węzłach chłonnych oraz płucach (w badaniu FDG-PET). A. W badaniu DxWBS uzyskano wynik ujemny, a sTg 
wynosiło 0,9 ng/ml; B. W badaniu FDG-PET MIP widoczne liczne przerzutowe węzły chłonne w prawej okolicy nadobojczykowej 
(SUV max: 28,6) oraz liczne guzowate przerzuty w płucach, w tym największy w segmencie przednim górnego płata prawego 
płuca (SUV max: 6,6)
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health services and elaborate patient screening with 
delicate medical instruments in our hospital. The series 
in the literature suggest a higher rate of recurrence in 
TCV, which is probably relevant to the older age (over 
50 years) at diagnosis [20]. Burman et al. reviewed 
76 patients with TCV and concluded that patients older 
than 50 years appeared more likely to have recurrences 
or die [10]. Although age was not a risk factor alone for 
metastasis, it was found as a risk factor together with 
other independent prognostic factors in our study 
(p = 0.022). Male sex according to female sex had 
been reported as a negative risk factor in the literature 
[2, 3, 9, 12]. We did not find sex as a critical parameter 
in the MG and NMG both in univariate (p = 0.154) and 
multivariate (p = 0.132) analyses in our study. Mean 
TS of TCV is higher than PTC. Mean TS of TCV in the 
study groups are around 4 cm [9, 10]. The mean TS of 
our patients was 27.5 mm, and this was lower than the 
literature. Again, we regard this with the early diag-
nosis provided by sophisticated medical devices and 
techniques leading to the early detection of thyroid 
pathologies. Mean TS was higher in the MG, and it was 
a significant risk factor in the study.
Michels et al. observed that TCV was slightly more 
multifocal than PTC in a cohort study of 778 patients with 
DTC [5]. In our study, 53.5% of the cases were multifocal, 
and we observed that MF did not constitute a risk factor 
for metastasis (p = 0.505). CI seems to be a more frequent 
pathologic feature in TCV than PTC. However, in our 
study, although CI was positive in 64% of the patients, it 
was not statistically significant (p = 0.073) between MG 
and NMG with regard to metastasis. Higher incidence 
of ETE in TCV patients was reported in the literature 
[5, 21–23]. Prendville et al. found ETE in 65% of their 
TCV group [24]. In our study, 35.5% of the cases had ETE 
and we found that it was not a risk factor for metastasis 
(p = 0.625). VI is not considered as a negative prognostic 
indicator in PTC. Hay et al. found that the presence of 
angioinvasion was not a significant factor in their cohort 
study of 1779 patients with PTC [25]. VI positivity is more 
common in TCV [18]. 37.5% of our patients had VI. On 
the other hand, we concluded that VI was a risk factor 
between MG and NMG in our study.
Higher incidence rates of pre-ablation LN metas-
tasis in TCV patients were reported in the literature 
[14, 18, 19, 26, 27]. There were central LN metastases 
in 37.5%, and lateral cervical LN metastasis in 44.5% 
of our cases. We found PACLNM and PACLLNM to be 
statistically significant in our study. It is remarkable that 
PACLLNM was slightly more sensitive than PACLNM. 
It was stated in the literature that TCV had more 
distant metastases than DTC [14, 18, 27, 28]. 12.5% of 
our patients had lung metastasis (detected by RxWBD 
or HRCT), and 9% had bone metastasis before the 
ablation therapy (detected by RxWBS, later supported 
by bone scintigraphy and MRI). PALM was proven as 
a risk factor in our study. Nevertheless, PABM was not 
a risk factor (p = 0.145), surprisingly. This inappropriate 
result can be simply explained by inadequate sampling 
number.
TCV patients present with advanced disease (stage 
III or IV) more often. Poor prognosis of TCV is frequent-
ly associated with stage. Recent large series support the 
thesis that poor prognosis is linked mainly to the stage 
[23, 28]. We determined stage as a very important inde-
pendent risk factor in the study. While stage III seemed 
to be a metastatic risk factor in our study (p = 0.004), 
stage IV interestingly was not (p = 0.058), in multivari-
ate analysis. A possible explanation for this discrepancy 
is insufficient sampling number in stage IV. If we had 
had enough patients in stage IV, we could have shown 
it, too. The circulating amount of Tg depends on the re-
sidual microscopic mass of thyroid tissue left over in the 
thyroid bed and/or metastatic tumour burden present in 
a DTC patient with total thyroidectomy [29, 30]. It is well 
documented in the literature that high PAsTg reflecting 
indirectly the existence of tumoural cells somewhere 
is a very important marker as a negative prognostic 
factor in PTC. This fact was somewhat accentuated for 
TCV. The mean PAsTg level of our patient group was 
290.5 ng/ml, and we found PAsTg to be the most acute 
risk factor acting on metastasis. It also emerged nega-
tively in this regard upon regression analysis.
Poor prognosis of TCV is certainly associated with 
grade [5]. But we could not examine the grade, i.e. the 
percentage of tall cell pattern, as an independent risk fac-
tor effecting metastasis in our study because we did not 
have this parameter definitely in most cases. We also did 
not compare molecular, genetic, and tumoural factors like 
Mucl1, type IV collagenase, and B-RAF between MG and 
NMG because we did not have enough data about these 
pathologic features. These are the limitations of our study.
In the follow-up, serial neck USG accompanied 
by Tg measurement indicated local recurrence and 
cervical LN metastasis in most of the patients. Even if 
Tg levels were in normal range in these patients, they 
were treated by surgical excision plus high-dose I-131. 
FDG-PET may detect local recurrence and/or distant 
metastasis in some patients whose DxWBS are negative 
but have high Tg levels indicating metastatic suspicion. 
Older age (over 57 years), larger tumours (over 4.5 cm), 
lenfovascular invasion, and stage IV are well-known 
poor prognostic factors [3, 6, 12]. In mortal cases of 
MG, mean age, TS, PAsTg, VI, PALM, PABM, and stage 
IV rates were seriously high according to survivors in 
both MG and NMG. Additionally, we found high PAsTg 
levels (over 400 ng/ml) to be an important prognostic 
factor in terms of mortality. 
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Although some recent studies claim that TCV his-
tology does not adversely affect prognosis, TCV is still 
a negative prognostic indicator in PTC and requires an 
aggressive therapeutic approach. As possibly as highest 
ablation doses (up to 9250–11110 MBq [250–300 mCi] 
calculated according to quantitative tumour or blood/ 
/whole-body dosimetry) have been recommended for 
the treatment by American Thyroid Association (ATA). 
For an absolute follow-up, it must benefit from all means 
of appropriate imaging methods. FDG-PET/CT plays 
a very important role in the follow-up of these patients 
in this sense. It is very useful for the detection of both lo-
cal recurrence and distant metastasis in patients whose 
DxWBS and neck USG are negative but who have high 
Tg levels implying metastasis.
Conclusions
TS, PAsTg, VI, PACLNM, PACLLNM, PALM, and stage 
are independent risk factors alone for TCV. However, 
age, PAsTg, and stage are more effective in metastatic 
development. Higher ablation doses should be admin-
istered to TCV patients having advanced stage (III, IV), 
high pre-ablation thyroglobulin level (over 400 ng/ml), 
and older age (over 52 years) especially with large 
tumour size (over 3.5 cm) and initial cervical lymph 
node metastasis. 
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